Newsroom | 94037 results

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of care (95% CI=0.75 [0.65; 0.87]; p=0.0001).1 These late-breaking data were presented today at the opening plenary sessi...

SIRACUSA, Nueva York--(BUSINESS WIRE)--Zetagen Therapeutics, biofarmacéutica privada de fase clínica pionera en terapias dirigidas contra el cáncer de mama primario y metastásico, acaba de anunciar que su artículo «Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-ally Noroxymorphone (NaN) Compared to Tamoxifen (TAM) and Abemaciclib (ABE)»...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Zetagen Therapeutics, une société biopharmaceutique privée spécialisée dans la recherche clinique, pionnière dans le domaine des thérapies ciblées innovantes pour le cancer du sein primaire et métastatique, a annoncé aujourd'hui que son résumé intitulé « Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-ally...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Zetagen Therapeutics, een particulier biofarmaceutisch bedrijf in de klinische fase dat baanbrekend werk verricht op het gebied van de eerste gerichte therapieën voor zowel primaire als gemetastaseerde borstkanker, heeft vandaag bekendgemaakt dat zijn abstract getiteld "Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Zetagen Therapeutics, azienda biofarmaceutica privata di fase clinica pioniera di terapie mirate prime nel loro genere per il carcinoma mammario primario e metastatico, oggi ha annunciato che il suo abstract intitolato “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-ally Noroxymorphone (NaN) Compared to T...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Zetagen Therapeutics, ein privat geführtes biopharmazeutisches Unternehmen im klinischen Stadium, das wegweisende, neuartige zielgerichtete Therapien für primären und metastasierten Brustkrebs entwickelt, gab heute bekannt, dass sein Abstrakt mit dem Titel „Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME) and N-a...

Lausanne, Suíça--(BUSINESS WIRE)--A Debiopharm (www.debiopharm.com), empresa biofarmacêutica suíça de capital privado dedicada ao desenvolvimento de terapias inovadoras que aumentem a qualidade de vida dos pacientes, anunciou hoje a conclusão bem-sucedida do recrutamento de pacientes em seu estudo clínico de fase III, aberto, de grupo único e multicêntrico (NCT06129539), denominado estudo LIBELULA™. O estudo avalia a eficácia, segurança e farmacocinética do Debio 4326 em pacientes pediátricos c...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with i...

GOLDEN, Colo. & CAIRO--(BUSINESS WIRE)--This partnership with EVA Pharma represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region....

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximately 24 months (the “Program”). “We believe Niagen Bioscience is an excellent investment and the Program is a compelling u...